




Searching News Database: Regeneron Pharmaceutical
HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
HSMN NewsFeed - 17 May 2022
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
HSMN NewsFeed - 25 Jul 2019
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team
HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
HSMN NewsFeed - 12 Feb 2018
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
HSMN NewsFeed - 14 Aug 2017
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 9 Feb 2017
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
HSMN NewsFeed - 4 Jan 2017
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
HSMN NewsFeed - 12 Sep 2016
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
HSMN NewsFeed - 26 Jun 2015
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
HSMN NewsFeed - 14 Jun 2010
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
HSMN NewsFeed - 23 Aug 2007
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
HSMN NewsFeed - 22 Aug 2007
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
HSMN NewsFeed - 8 Aug 2007
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
HSMN NewsFeed - 5 Feb 2007
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
HSMN NewsFeed - 20 Dec 2006
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
HSMN NewsFeed - 3 Oct 2006
Regeneron Names Peter Powchik, M.D., Senior Vice President of Clinical Development
Regeneron Names Peter Powchik, M.D., Senior Vice President of Clinical Development
HSMN NewsFeed - 31 May 2006
Regeneron Receives Fast-Track Designation for the IL-1 Trap in CIAS1-Associated Periodic Syndromes (CAPS)
Regeneron Receives Fast-Track Designation for the IL-1 Trap in CIAS1-Associated Periodic Syndromes (CAPS)
Additional items found! 27

Members Archive contains
27 additional stories matching:
Regeneron Pharmaceutical
(Password required)
Regeneron Pharmaceutical
(Password required)